INFI Upcoming Earnings (Q3 2023)
|Earnings Date:||Nov 13, 2023|
Current P/E* ratio: -1.21 | Price (Sep 20, 2023, EOD): $0.0229
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for INFI Premium
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the tre... INFI Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.